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Abstract
Background: The aim of this study was to determine which predictors influence the risk of relapse among a cohort
of amphetamine-type substance (ATS) users in Iran.
Methods: A Cox proportional hazards model was conducted to determine factors associated with the relapse time
in the Matrix treatment program provided by the Iranian National Center of Addiction Studies (INCAS) between
March 2010 and October 2011.
Results: Participating in more treatment sessions was associated with a lower probability of relapse. On the other
hand, patients with less family support, longer dependence on ATS, and those with an experience of casual sex and
a history of criminal offenses were more likely to relapse.
Conclusion: This study broadens our understanding of factors influencing the risk of relapse in ATS use among an
Iranian sample. The findings can guide practitioners during the treatment program.
Keywords: ATS dependence, Matrix model, Treatment program, Relapse, Survival analysis
Background
Amphetamine-type substance (ATS) refers to the varying
forms of stimulant drugs such as methamphetamine,
amphetamine, methylenedioxymethamphetamine (MDMA,
also known as “ecstasy”), methcathinone, and ephedrine.
ATS is the second most commonly used illicit drug type
worldwide after cannabis [1, 2]. The non-medical use of
ATS poses potential health problems. Several studies re-
ported that ATS dependence contributes to physical and
psychiatric diseases, including heart damage, brain damage,
impaired thinking, mood disturbance, aggression, violence,
cognitive impairment, psychotic symptoms, poisoning,
and even death [3]. Furthermore, ATS dependence is
associated with increased financial problems, delinquency,
and communication difficulties [3, 4]. In Iran, drug de-
pendence has become more and more of both a social and
a health problem. While opioid consumption has a long
history in Iran, the use of stimulant drugs such as ATS
started to rise around 2000 [5, 6]. The growing rate of
stimulant use in Iran is rooted in the easy availability of
ATS, increased prices of opium, curiosity for this new type
of drug, public ignorance about the dangers of ATS
dependence, and expectation of sexual benefits during
ATS use [5].
However, little is known about the rate of stimulant
drug use in Iran, mainly because it is a relatively new
phenomenon in this country [7]. Some recent studies
have suggested a large number of stimulant users [7, 8].
For instance, in a study conducted by Hajiabdolbaghi
and colleagues in which the sexual behaviour among a
group of at-risk women in Tehran was investigated, the
authors found that 18.5 % of people aged between 15
and 25 years old reported they had used illicit substances,
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including ATS [9]. In addition, cases of cardiomyopathy,
paranoia, suicide, and homicide resulting from ATS use
have become more prominent in medical and psychiatric
emergencies in Iran [5]. Furthermore, because these
stimulant drugs can be injected, they have become as-
sociated with the transmission of infectious diseases
such as HIV/AIDS and hepatitis, both of which are
already major health problems among the drug dependents
in Iran [10, 11].
As a response to the emerging health and social crises
related to ATS, in 2007 the Iranian National Center for
Addiction Studies (INCAS) started a pilot of the Matrix
program as a cognitive-behavioral intervention and has
continued to focus on this problem since that time. The
program was named after the Matrix Center in Southern
California, the treatment center in which the program
was initially founded [12]. Originally developed for the
treatment of cocaine, the Matrix model is a “multi-element
package of therapeutic strategies” that includes cognitive-
behavioral therapy, research on relapse prevention, mo-
tivational interviewing strategies, psycho-educational
information, and 12-step program involvement [13].
Several studies have supported that cognitive-behavioral
interventions are effective treatments for stimulant drug
dependencies [12, 13].
Relapse is however a major difficulty in addiction
treatment. Indeed, others studies confirmed the high
rate of relapse in ATS users [14–18]. For example, one
study conducted by Brecht and Herbeck (2014) showed
that 61 % of the methamphetamine users relapsed within
1 year following treatment discharge [18]. Relapse is not
the result of a single factor and is usually caused by a com-
bination of demographic and physiological characteristics,
situational and socio-cultural features, and treatment char-
acteristics [18–22]. While, most previous studies investi-
gated correlates of relapse into drug use among opioid
dependents [19, 20, 23–29], few studies focused on factors
related to relapse among ATS users including demo-
graphic predictors such as age [22, 28]; gender [30];
education attainment [22]; receiving social support [28];
patients’ psychological comorbidities [22, 28, 31]; history
of prison [28]; and drug-use characteristics, such as age of
starting ATS use [20], history of drug injection [32], selling
substances [20, 33], duration of lifetime ATS dependence
[31], and treatment characteristics (including age of par-
ticipating in treatment program [22] and type of treatment
[12, 20, 34]). However, at this point there is no sufficient
evidence for pattern of time to relapse among ATS users.
Thus, the goal of this study is to examine covariates asso-
ciated with time to relapse in ATS users who participated
in the Matrix treatment program focussing specially on
examination of the contribution of the Matrix program
for reducing the risk of relapse. We ran a multivariate
Cox proportional hazards regression model as a semi-
parametric survival model to study the factors associated
with time to relapse into ATS usage. The results can help
to predict which clients are more at risk for relapse. As
such, the findings may have wider relevance to therapists
and practitioners who have to identify people who are sus-
ceptible to relapse and, as such, prevent them from actual
relapse by offering them additional services.
Method
Participants
The study used a retrospective cohort design. The data
were collected from March 2010 until October 2011. A
total of 168 ATS users entered the Matrix treatment
program run by INCAS. However, 39 clients who dis-
continued their contact with the therapists at INCAS
were excluded from the analyses because there was no
follow-up data for them. To test for possible biases, the
39 clients with missing data were compared with the rest
of the sample. As shown in Tables 1 and 2, no significant
differences were found between the 39 clients and the
rest of the sample regarding any of the background vari-
ables. This indicated that the 39 clients with missing
follow-up data were not systematically different from
those who completed the program. Of the 129 partici-
pants who completed the follow-up period, there was
only one woman. This female participant was excluded
from the sample for statistical reasons. Thus, our ana-
lyses of time to relapse were conducted on 128 males.
This study was approved by the ethical committee of
Tehran University of Medical Sciences. The program
was explained to each participant, and informed consent
was obtained from all patients prior to their participation
in the study.
Study design
According to INCAS policy, a fee of 1,000,000 rials
(approximately 35 USD, with an official minimum
wage of 300 USD) was mandatory prior to admission
to the program. The inclusion criteria of the treatment
program were as follows: (1) being dependent to ATS,
according to the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV) and (2)
being at least 18 years old at the time of admission.
The authors collected information on the patients over
8 months. Patients were monitored during a 2-month
treatment program and after the treatment program,
for a follow-up period of 6 months. All patients gave the
information that was required; hence, there were no miss-
ing data on the 128 patients included in the analyses.
Relapse criteria were defined as both a positive urinary
ATS test and a return to ATS use reported by the patients
or their family members. Patients had regular urine ana-
lysis tests, i.e., twice in the 1st month after starting the
treatment program and once in the following months. At
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the end of the follow-up period, the researchers contacted
the family members of the patients and asked them about
the patients’ relapse during the treatment program and the
follow-up period. Of the 128 patients, 49 patients (38 %)
had not relapsed by the end of the follow-up period.
The Matrix program
The treatment program consisted of up to 29 sessions of
individual counselling, but the average number of sessions
completed was 13. All sessions were held at INCAS in the
2 months after starting the treatment program for each
patient. Since INCAS is an outpatient centre, participating
in each counselling session was voluntary. Consultants
were experienced psychologists working as INCAS staff.
All consultants had been trained for about 80 hours to ob-
tain enough knowledge of and experience with the Matrix
model before starting the program. During each session, a
consultant talked with the client about a single topic. The
aim was to help patients cope with difficulties they faced
during recovery. The topics included deal with cravings,
impulsive sexual behaviors, lack of energy, dealing with
families’ distrust, sense of shame or guilt, unwanted be-
haviors, and emotions resulting in drug use. Further,
the consultants identified opportunities that facilitated
patients’ treatment including motivation, honesty, and
employment. Patients were also required to do some
homework in order to improve their social skills.
Data collection and study variables
In this study, the outcome variable was time to relapse
into ATS use since starting the treatment program. Several
demographic and psychological characteristics of the
respondents were collected at the intake. Data were
collected on sex, age at the time of admission to the
program, high school graduation (yes/no), marital sta-
tus (single, married, divorced), and employment status
(full time, part time, unemployed). With regard to the
psychological characteristics, data were collected on ag-
gression experiences (yes/no), history of criminal offences
(yes/no) and history of casual sexual relationships (yes/no)
during the 6 months before admission to the treatment
program.
Table 1 Demographic and psychological characteristics of the sample
Patients included (n = 128) Patients excluded (n = 39)
n Mean/% n Mean/% p value
Demographic variables
Age at the time of admission 128 30.10 39 30.00 .99b
High school graduate
Yes 78 60.93 % 24 61.53 % .99a
No 50 39.06 % 15 38.46 %
Marital status .89a
Single 56 43.75 % 18 46.15 %
Married 45 35.16 % 12 30.77 %
Divorced 27 21.09 % 9 23.08 %
Employment status .95a
Full time 56 43.75 % 16 41.03 %
Part time 24 18.75 % 8 20.51 %
Unemployed 48 37.50 % 15 38.46 %
Psychological variables
Aggression .99a
Yes 73 57.03 % 22 56.41 %
No 55 42.97 % 17 43.59 %
Criminal offences .79a
Yes 36 28.15 % 12 30.77 %
No 92 71.88 % 28 71.80 %
Casual sex .99a
Yes 100 78.13 % 29 74.36 %
No 28 21.88 % 10 25.64 %
Note
achi-square test; bt-test
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Furthermore, different predictors that might be associ-
ated with the risk of relapse into ATS use were analysezed.
The main predictor of interest was the Matrix treatment
program, assessed by the number of consultation and
training sessions that each patient attended. In addition,
data were collected on age at first drug use, drug injection
experience (yes/no), duration of drug dependence in gen-
eral (in years), duration of ATS dependence (in years),
having another addicted family member (yes/no), self-
reported family support (yes/no), and poly-substance use
(yes/no), which was defined as using opioids —especially
opium and heroin— crack, and cannabis, as well as alco-
hol, during the period of ATS dependence (not lifetime) at
least 4 times a week.
Data analysis
The inclusion of the study variables allowed the re-
searchers to predict which clients were more at risk for
relapse. To do so, we applied a Cox proportional hazards
regression model as a semi-parametric method of survival
analysis. Survival models are preferred over classic regres-
sion models (such as a logistic regression) because the
former analyzes both the time elapsed before an event and
the probability of occurrence of the event. The Cox model
is based on the assumption of the proportionality of haz-
ards, meaning that the hazard ratio of each variable does
not change over time [35].We assessed this assumption
based on a goodness of fit test. Data analyses were per-
formed using Stata version 11.
Results
Description of the sample
Descriptive characteristics of the 128 patients are shown
in Tables 1 and 2. At the time of admission, the mean
age of the study participants was 30.1 years. Thirty-nine
present of the patients had dropped out of high school.
With regard to marital status, about 44 were single, 35
were married, and 21 were divorced. Of the 63 % of the
sample who had a job, about 44 % worked full time. The
mean age of starting drug use was 22 years. The median
Table 2 Drug related characteristics of the sample
Patients included (n = 128) Patients excluded (n = 39)
n Mean/% n Mean/% p value
Age at first time of drug use 128 22.00 39 21.32 .68b
Duration of Addiction (in years) 128 5.20 39 5.25 .99b
Duration of amphetamines dependence (in years) 128 2.20 39 2.02 .79b
Family support .99a
Yes 32 25.00 % 9 23.08 %
No 96 75.00 % 30 76.92 %
Having (at least) an addict in the family .79a
Yes 46 35.94 % 13 33.33 %
No 82 64.06 % 26 66.67 %
Injection experience .59a
Yes 26 20.31 % 9 23.08 %
No 102 79.69 % 30 76.92 %
Poly substance abuse .63a
Yes 110 85.94 % 32 82.05 %
No 18 14.06 % 7 17.95 %
Amphetamines dependence as the primary diagnosis .99a
Yes 113 88.29 % 34 87.18 %
No 18 11.72 % 5 12.82 %
Treatment experience .99a
Yes 95 74.22 % 29 74.36 %
No 33 25.78 % 10 25.64 %
A history of residential treatment in camps .76a
Yes 78 60.94 % 22 56.41 %
No 50 39.06 % 17 43.59 %
Note.
achi-square test; bt-test
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lifetime periods of drug dependence in general and ATS
dependence in particular before intake were 48 and
24 months, respectively.
Few patients (20 %) had practised drug injection, but
most (86 %) had engaged in poly-substance use before
starting the treatment program. For many of the partici-
pants (88 %), ATS dependence was the primary diagnosis.
According to the patients’ self-reports, 57 had a history of
aggressive behaviors, and 28 % had been arrested at least
once for criminal offences. However, no one had been in-
volved in any violent criminal activities. Almost 78 % re-
ported having had casual sexual relationships. A minority
of participants (25) reported that they were receiving
passable or strong family support, and around 36 %
said that at least one of their family members was also
drug dependent. The majority of patients (74 %) had
previously enrolled in other stimulant drug treatment
programs, and about 61 % had tried residential treatment
programs. Most of the patients (98 %) were dependent on
methamphetamines, while 2 % were dependent on ecstasy.
Nearly 62 % of the patients relapsed into ATS dependence
during the treatment program or in the 6-month follow-
up period.
Figure 1 illustrates Kaplan–Meier estimates of relapse
rates among the patients. The rates of time to relapse for
30 days, 90 days, and 180 days from the time of admission
were 68, 24, and 11 %, respectively.
Multivariate analysis
A normal Cox regression was performed to examine the
relationship between potential predictors related to risk
of relapse.
As indicated in Table 3 and Fig. 2, all significant predic-
tors in the Cox model satisfied the proportional hazard
(PH) assumption according to the goodness-of-fit test
(based on the Schoenfeld residuals), pointing us toward
the Cox proportional hazards model. As shown in Table 4,
five predictors —including Matrix treatment attendance,
casual sex habits, criminal offences, family support, and
lifetime duration of ATS dependence— were found to be
significant. More specifically, estimated hazard ratios
(HRs) suggest that, on average, the rate of relapse into the
drug reduced by 18 per each additional session of consult-
ation and training attended (HR = .82, p = 0.000). In
addition, on average, patients with a history of casual
sex habits had a shorter time to relapse compared to
the other group (HR = 2.03, p = 0.025). The rate of re-
lapse to drug among patients with a history of criminal
offence was .59 higher compared to the other group
(HR = 1.59, p = 0.033). Furthermore, passable or strong
family support was a predictor of longer time to relapse
(HR = 0.52, p = 0.003). Finally, the risk of relapse into drugs
increased .02 per every one year of ATS dependence before
intake to the Matrix program (HR= 1.02, p = 0.001).
Discussion
To the best of our knowledge, this is the first study con-
ducted among ATS users in Iran in which the predictors
of time to relapse into ATS use were examined while
undergoing the Matrix treatment program, carried out
at INCAS. This information can fill in important gaps in
our knowledge about a drug that has only recently be-
come a major area of concern in Iran.
In this study, over half of the participants relapsed
(61 %). This finding is consistent with similar studies
Fig. 1 Kaplan-Meier estimate of time to relapse
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that confirmed a high rate of relapse into ATS use after
treatment discharge [14–18]. Using a Cox proportional
hazards model, a greater number of Matrix sessions was
found to be associated with a lower risk of relapse into
ATS use. The more consultation and training sessions that
patients attended, the longer time to relapse they had. The
results thus support the value of treatment sessions in
reducing relapse risk and, in particular, of encouraging
clients to attend as many of the treatment sessions as
they can. Although the findings of one previous study
suggested the Matrix treatment program was related to
longer retention time [12], it did not focus on the exact
effect of attendance in consultation sessions.
An influential predictor of shorter time to relapse into
ATS use was casual sex history. Patients engaging in casual
sex prior to the treatment enrolment faced higher risk of
relapse. This finding is in line with other studies on dif-
ferent kinds of drug dependencies [36, 37]. This effect
may be related to this idea that being in a less stable re-
lationship results in less compliance with treatment
programs. In addition, the motivation for re-experiencing
sex under influence of stimulants might relate to this
Table 3 Test of proportional hazard assumption
Variable rho chi2 df prob > chi2
The Matrix treatment program
(in sessions)
0.05 0.61 1 0. 44
Casual sex −0.07 0.33 1 0.57
Criminal offences 0.15 1.46 1 0.23
Duration of amphetamines dependence
(in years)
0.01 0.00 1 0.96
Family support 0.01 0.00 1 0.95
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result. Furthermore, our results are consistent with pre-
vious studies in which it was found that a history of
criminal offences before intake increases the risk of
treatment dropout [38, 39].
Interestingly, this study found that strong family sup-
port was associated with longer time to relapse (i.e. they
were less at risk of relapse to ATS use). This finding is
in line with the results of other studies focussing on dif-
ferent treatment for various types of drug dependencies
[40, 41]. Patients receiving family support have usually
enhanced their mental health, which determines better
treatment outcomes [42]. Further, family support for
regular attendance of treatment sessions, the family’s role
in coping with drug cravings and/or providing a support-
ing environment for treatment at home, and patients’ de-
sire to satisfy their families are other explanations for
good treatment outcomes.
Furthermore, another factor that was associated with a
shorter time to relapse was duration of lifetime period of
ATS dependence before starting the treatment. This
finding is consistent with the results of other studies fo-
cussing specially on cocaine addiction [43–45] and sug-
gests that people who have been drug users for a long
period of time have more difficulty remaining abstinent
than others [31, 44].
None of the demographic variables were significant
associated with relapse to ATS in this study While,
some previous studies have shown associations between
demographic variables and relapse to ATS [22, 28], two
other studies found results similar to our study. One
explanation may be the spread of drug abuse among
people with different age, occupation, education, and
other backgrounds.
It is interesting that nearly all of the patients who
joined our treatment program were males. There are
several explanations for this gender discrepancy. First,
ATS dependence is not common among Iranian women
[46, 47]. Second, less social and family support is given
to drug-dependent women in Iran. In general, women
might feel greater stigma than men about treatment,
providing the women with fewer opportunities to partici-
pate in treatment programs [48]. Finally, drug-dependent
women might experience more difficulties paying for the
treatment sessions than men because of the high un-
employment rate among Iranian women.
This study was subject to some limitations. First, al-
most all the information was collected according to the
patients’ self-reports. As such, comorbidities specified
along with their drug dependence diagnosis were not
based on a systematic professional diagnosis. Further-
more, patients are not always aware of their drug-use
characteristics such as time of initiation of dependence.
Therefore, a better but more time-consuming approach
to access these variables would be to ask about each cri-
terion of dependence separately and the time of initi-
ation of each criterion. Second, all study members were
male; therefore, the results cannot be generalised to both
sexes. Third, most information for both included and ex-
cluded clients was collected at the baseline, and we did
not consider the time varying covariates. Finally, several
variables related to treatment program, such as the quality
of services and rapport between patients and therapists,
that might influence the relapse rate were not considered
in this study because of a lack of any information on
which to test them.
Conclusion
Participating in more treatment sessions is associated
with less risk of relapse. Still, more attention, help, and
consultations should be given to patients with less fam-
ily support, longer dependence on ATS, and those with
a history of casual sex and/or of criminal offences. The
findings can guide practitioners during the treatment
program.
Table 4 Cox PH model of stimulants relapse predictors
Variable Hazard ratio Robust SE Confidence of interval (95 %) p-value
The Matrix treatment program (in sessions) .82 .04 .75 .9 0.000
Casual sex
Yes 2.03 .65 1.09 3.79 0.025
No - - - - -
Criminal offences
Yes 1.59 .35 1.04 2.45 0.033
No - - - - -
Duration of Amphetamines dependence (in years) 1.02 .01 1.01 1.03 0.001
Family support
Yes .52 .12 .33 .80 0.003
No - - - - -
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